Calcitonin Injection Global Market Report 2025

The calcitonin injection market size has grown strongly in recent years. It will grow from $0.67 billion in 2024 to $0.73 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. Growth during the historic period can be attributed to the rising prevalence of osteoporosis, increased awareness of bone health, expansion of treatment options for postmenopausal women, the availability of government healthcare subsidies, and a growing geriatric population.

The calcitonin injection market size is expected to see strong growth in the next few years. It will grow to $0.99 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. Growth in the forecast period can be attributed to increasing demand for bone-related treatments, the emergence of biosimilar competition, rising demand in emerging markets, a shift toward personalized medicine, and expanding research into alternative applications of calcitonin. Key trends expected during this period include advancements in intranasal and injectable delivery systems, the development of extended half-life formulations, the introduction of biosimilar calcitonin products, innovation in osteoporosis treatment approaches, and improvements in diagnostic technologies.

The rising prevalence of osteoporosis is expected to drive the growth of the calcitonin injection market in the coming years. Osteoporosis is a condition marked by reduced bone density and increased susceptibility to fractures, primarily affecting older adults, particularly postmenopausal women. This growing prevalence is largely attributed to the aging global population, as extended life expectancy contributes to natural bone loss and a heightened risk of osteoporosis. Calcitonin injections play a key role in managing the condition by regulating calcium levels and slowing bone degradation, thereby helping to preserve bone density. Their ease of administration also enhances patient adherence and reduces the risk of fractures. For example, in June 2024, the Australian Institute of Health and Welfare reported that 853,600 people (3.4% of the population) were living with osteoporosis or osteopenia in 2022, accounting for 2,659 deaths, or 1.4% of all recorded deaths. Thus, the growing burden of osteoporosis is fueling demand for calcitonin injections.

Leading companies in the calcitonin injection market are emphasizing the development of innovative products such as USP synthetic injections to improve treatment efficacy and patient outcomes. USP synthetic injections are formulated with synthetically produced active ingredients that comply with the rigorous quality, purity, strength, and identity standards set by the United States Pharmacopeia (USP). These products are manufactured under stringent conditions to ensure safety and therapeutic effectiveness. For example, in February 2025, Fresenius Kabi, a Germany-based pharmaceutical company, launched a USP synthetic calcitonin salmon injection for the treatment of symptomatic Paget’s disease of bone and hypercalcemia. This sterile solution is designed for intramuscular or subcutaneous use, provided at a concentration of 200 USP units per mL and packaged in a 2 mL multi-dose vial (400 USP units). The injection must be refrigerated between 2°C and 8°C. Acting as a calcium regulator, it is indicated for cases where alternative therapies are unsuitable, including hypercalcemia and postmenopausal osteoporosis.

In April 2022, Hikma Pharmaceuticals plc, a UK-based pharmaceutical company, acquired Custopharm Inc. for an undisclosed sum. This acquisition was intended to bolster Hikma’s U.S. injectables division by broadening its product range, advancing its research and development capabilities, and accelerating growth in the generic sterile injectable market. Custopharm Inc., based in the U.S., develops calcitonin salmon injection marketed under the brand name Calcimar.

Major players in the calcitonin injection market are Kaiser Permanente, F. Hoffmann-La Roche AG, Sanofi S.A., Novartis AG, AstraZeneca plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Fresenius Kabi AG, Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Limited, Cipla Limited, Hikma Pharmaceuticals plc, Endo International plc, Asahi Kasei Pharma Corporation, Torrent Pharmaceuticals Limited, BCN Peptides S.L., SG Pharmaceuticals Pvt Ltd, Leucadia Pharmaceuticals Inc., Polypeptide Group AB.

North America was the largest region in the calcitonin injection market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in calcitonin injection report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the calcitonin injection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Calcitonin injection is a medication used to treat a range of bone-related conditions by inhibiting bone resorption and increasing calcium excretion through the kidneys. It is commonly administered via subcutaneous or intramuscular injection and is often derived from salmon, which exhibits a similar but more potent effect compared to human calcitonin.

The main types of calcitonin injection include salmon calcitonin, human calcitonin, and synthetic calcitonin. Salmon calcitonin refers to a form of the hormone either synthesized or derived from salmon, known for its higher potency. These injections can be administered through various routes, such as intravenous (IV), subcutaneous, or intramuscular methods. Distribution channels for these medications include direct sales, online pharmacies, retail pharmacies, and healthcare institutions. Calcitonin injections fall under several drug classes, including treatments for osteoporosis, Paget’s disease, hypercalcemia, and bone metastases. They are utilized by various end users, such as hospitals, specialty clinics, geriatric care facilities, and home healthcare providers.

The calcitonin injection market research report is one of a series of new reports that provides calcitonin injection market statistics, including calcitonin injection industry global market size, regional shares, competitors with a calcitonin injection market share, calcitonin injection market segments, market trends and opportunities, and any further data you may need to thrive in the calcitonin injection industry. This calcitonin injection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The calcitonin injection market consists of sales of combination therapy packs, single-dose and multi-dose vials, branded formulations and generic versions of calcitonin products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.